Evidence map›Paper›PMID 40919245›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025

Response of MDA-MB231 cells to cisplatin and paclitaxel - viability, migration and gene expression estimation in mono- and co-culture with macrophages.

Brygida Rusiecka, Oliwia Piwocka, Agnieszka Knopik-Skrocka

Abstract read
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Brygida Rusiecka *Faculty of Biology, Adam Mickiewicz University, Poznan, Poland.
Oliwia Piwocka *Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.
Agnieszka Knopik-SkrockaDepartment of Cell Biology, Faculty of Biology, Adam Mickiewicz University, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) shows a high aggressiveness and chemoresistance. It is important to understand the biology of TNBC, including the influence of immune cells, such as macrophages, on cancer cells (CCs) and their response to chemotherapeutics. The research aimed to determine the effect of cisplatin (CisPt) and paclitaxel (PTX) on the viability, migratory ability and expression of selected genes of TNBC cells co-cultured with macrophages. The influence of macrophages alone on CCs was also studied. Materials and methods: The experiments were conducted with TNBC cell line (MDA-MB 231) and macrophages (THP1) in four experimental setups: MDA-MB231; MDA-MB231 + THP1; MDA-MB231 + CisPt or PTX; MDA-MB231 + THP1 + CisPt or PTX, using cytotoxicity and wound healing (WH) assays, flow cytometry and quantitative polymerase chain reaction (qPCR). Results: Under PTX action, but not CisPt, a significant decrease in the number of MDA-MB 231 cells and their migration ability was observed. The presence of THP1 cells increases the survival of MDA-MB231 cells treated with CisPt, not PTX. A heat-map with the gene expression level has revealed that under THP1 CCs treated with PTX increase Conclusion: PTX is more toxic against MDA-MB231 cells than CisPt. M2 macrophages play an important role in MDA-MB231 cells gene expression, inducing changes in their metabolism and phenotype.

Indexed as

chemotherapeuticsgene expressionmacrophagesmigrationtriple-negative breast cancerviability

Identifiers

PMID40919245
PMCPMC12413220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.